Cargando…

Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice

Background and Objectives: Colorectal cancer (CRC) is a leading cause of cancer-related mortality and morbidity worldwide. Bevacizumab was approved for the treatment of metastatic colorectal cancer (mCRC) based on favorable benefit-risk assessments from randomized controlled trials, but evidence on...

Descripción completa

Detalles Bibliográficos
Autores principales: Dinu, Ioana Mihaela, Mihăilă, Mariana, Diculescu, Mircea Mihai, Croitoru, Vlad Mihai, Turcu-Stiolica, Adina, Bogdan, Diana, Miron, Monica Ionela, Lungulescu, Cristian Virgil, Alexandrescu, Sorin Tiberiu, Dumitrașcu, Traian, Buică, Florina, Luca, Ioana Niculina, Lungulescu, Cristina, Negulescu, Madalina Cristina, Gramaticu, Iulia Magdalena, Cazacu, Irina Mihaela, Croitoru, Adina Emilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963555/
https://www.ncbi.nlm.nih.gov/pubmed/36837551
http://dx.doi.org/10.3390/medicina59020350
_version_ 1784896280954142720
author Dinu, Ioana Mihaela
Mihăilă, Mariana
Diculescu, Mircea Mihai
Croitoru, Vlad Mihai
Turcu-Stiolica, Adina
Bogdan, Diana
Miron, Monica Ionela
Lungulescu, Cristian Virgil
Alexandrescu, Sorin Tiberiu
Dumitrașcu, Traian
Buică, Florina
Luca, Ioana Niculina
Lungulescu, Cristina
Negulescu, Madalina Cristina
Gramaticu, Iulia Magdalena
Cazacu, Irina Mihaela
Croitoru, Adina Emilia
author_facet Dinu, Ioana Mihaela
Mihăilă, Mariana
Diculescu, Mircea Mihai
Croitoru, Vlad Mihai
Turcu-Stiolica, Adina
Bogdan, Diana
Miron, Monica Ionela
Lungulescu, Cristian Virgil
Alexandrescu, Sorin Tiberiu
Dumitrașcu, Traian
Buică, Florina
Luca, Ioana Niculina
Lungulescu, Cristina
Negulescu, Madalina Cristina
Gramaticu, Iulia Magdalena
Cazacu, Irina Mihaela
Croitoru, Adina Emilia
author_sort Dinu, Ioana Mihaela
collection PubMed
description Background and Objectives: Colorectal cancer (CRC) is a leading cause of cancer-related mortality and morbidity worldwide. Bevacizumab was approved for the treatment of metastatic colorectal cancer (mCRC) based on favorable benefit-risk assessments from randomized controlled trials, but evidence on its use in the real-world setting is limited. The aim of the current study is to evaluate the outcomes and safety profile of bevacizumab in mCRC in a real-world setting in Romania. Patients and Methods: This was an observational, retrospective, multicentric, cohort study conducted in Romania that included patients with mCRC treated with bevacizumab as part of routine clinical practice. Study endpoints were progression-free survival, overall survival, adverse events, and patterns of bevacizumab use. Results: A total of 554 patients were included in the study between January 2008 and December 2018. A total of 392 patients (71%) received bevacizumab in the first line and 162 patients (29%) in the second line. Bevacizumab was mostly combined with a capecitabine/oxaliplatin chemotherapy regimen (31.6%). The median PFS for patients treated with bevacizumab was 8.4 months (interquartile range [IQR], 4.7–15.1 months) in the first line and 6.6 months (IQR, 3.8–12.3 months) in the second line. The median OS was 17.7 months (IQR, 9.3–30.6 months) in the first line and 13.5 months (IQR, 6.7–25.2 months) in the second line. Primary tumor resection was associated with a longer PFS and OS. The safety profile of bevacizumab combined with chemotherapy was similar to other observational studies in mCRC. Conclusions: The safety profile of bevacizumab was generally as expected. Although the PFS was generally similar to that reported in other studies, the OS was shorter, probably due to the less frequent use of bevacizumab after disease progression and the baseline patient characteristics. Patients with mCRC treated with bevacizumab who underwent resection of the primary tumor had a higher OS compared to patients with an unresected primary tumor.
format Online
Article
Text
id pubmed-9963555
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99635552023-02-26 Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice Dinu, Ioana Mihaela Mihăilă, Mariana Diculescu, Mircea Mihai Croitoru, Vlad Mihai Turcu-Stiolica, Adina Bogdan, Diana Miron, Monica Ionela Lungulescu, Cristian Virgil Alexandrescu, Sorin Tiberiu Dumitrașcu, Traian Buică, Florina Luca, Ioana Niculina Lungulescu, Cristina Negulescu, Madalina Cristina Gramaticu, Iulia Magdalena Cazacu, Irina Mihaela Croitoru, Adina Emilia Medicina (Kaunas) Article Background and Objectives: Colorectal cancer (CRC) is a leading cause of cancer-related mortality and morbidity worldwide. Bevacizumab was approved for the treatment of metastatic colorectal cancer (mCRC) based on favorable benefit-risk assessments from randomized controlled trials, but evidence on its use in the real-world setting is limited. The aim of the current study is to evaluate the outcomes and safety profile of bevacizumab in mCRC in a real-world setting in Romania. Patients and Methods: This was an observational, retrospective, multicentric, cohort study conducted in Romania that included patients with mCRC treated with bevacizumab as part of routine clinical practice. Study endpoints were progression-free survival, overall survival, adverse events, and patterns of bevacizumab use. Results: A total of 554 patients were included in the study between January 2008 and December 2018. A total of 392 patients (71%) received bevacizumab in the first line and 162 patients (29%) in the second line. Bevacizumab was mostly combined with a capecitabine/oxaliplatin chemotherapy regimen (31.6%). The median PFS for patients treated with bevacizumab was 8.4 months (interquartile range [IQR], 4.7–15.1 months) in the first line and 6.6 months (IQR, 3.8–12.3 months) in the second line. The median OS was 17.7 months (IQR, 9.3–30.6 months) in the first line and 13.5 months (IQR, 6.7–25.2 months) in the second line. Primary tumor resection was associated with a longer PFS and OS. The safety profile of bevacizumab combined with chemotherapy was similar to other observational studies in mCRC. Conclusions: The safety profile of bevacizumab was generally as expected. Although the PFS was generally similar to that reported in other studies, the OS was shorter, probably due to the less frequent use of bevacizumab after disease progression and the baseline patient characteristics. Patients with mCRC treated with bevacizumab who underwent resection of the primary tumor had a higher OS compared to patients with an unresected primary tumor. MDPI 2023-02-13 /pmc/articles/PMC9963555/ /pubmed/36837551 http://dx.doi.org/10.3390/medicina59020350 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Dinu, Ioana Mihaela
Mihăilă, Mariana
Diculescu, Mircea Mihai
Croitoru, Vlad Mihai
Turcu-Stiolica, Adina
Bogdan, Diana
Miron, Monica Ionela
Lungulescu, Cristian Virgil
Alexandrescu, Sorin Tiberiu
Dumitrașcu, Traian
Buică, Florina
Luca, Ioana Niculina
Lungulescu, Cristina
Negulescu, Madalina Cristina
Gramaticu, Iulia Magdalena
Cazacu, Irina Mihaela
Croitoru, Adina Emilia
Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice
title Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice
title_full Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice
title_fullStr Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice
title_full_unstemmed Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice
title_short Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice
title_sort bevacizumab treatment for metastatic colorectal cancer in real-world clinical practice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963555/
https://www.ncbi.nlm.nih.gov/pubmed/36837551
http://dx.doi.org/10.3390/medicina59020350
work_keys_str_mv AT dinuioanamihaela bevacizumabtreatmentformetastaticcolorectalcancerinrealworldclinicalpractice
AT mihailamariana bevacizumabtreatmentformetastaticcolorectalcancerinrealworldclinicalpractice
AT diculescumirceamihai bevacizumabtreatmentformetastaticcolorectalcancerinrealworldclinicalpractice
AT croitoruvladmihai bevacizumabtreatmentformetastaticcolorectalcancerinrealworldclinicalpractice
AT turcustiolicaadina bevacizumabtreatmentformetastaticcolorectalcancerinrealworldclinicalpractice
AT bogdandiana bevacizumabtreatmentformetastaticcolorectalcancerinrealworldclinicalpractice
AT mironmonicaionela bevacizumabtreatmentformetastaticcolorectalcancerinrealworldclinicalpractice
AT lungulescucristianvirgil bevacizumabtreatmentformetastaticcolorectalcancerinrealworldclinicalpractice
AT alexandrescusorintiberiu bevacizumabtreatmentformetastaticcolorectalcancerinrealworldclinicalpractice
AT dumitrascutraian bevacizumabtreatmentformetastaticcolorectalcancerinrealworldclinicalpractice
AT buicaflorina bevacizumabtreatmentformetastaticcolorectalcancerinrealworldclinicalpractice
AT lucaioananiculina bevacizumabtreatmentformetastaticcolorectalcancerinrealworldclinicalpractice
AT lungulescucristina bevacizumabtreatmentformetastaticcolorectalcancerinrealworldclinicalpractice
AT negulescumadalinacristina bevacizumabtreatmentformetastaticcolorectalcancerinrealworldclinicalpractice
AT gramaticuiuliamagdalena bevacizumabtreatmentformetastaticcolorectalcancerinrealworldclinicalpractice
AT cazacuirinamihaela bevacizumabtreatmentformetastaticcolorectalcancerinrealworldclinicalpractice
AT croitoruadinaemilia bevacizumabtreatmentformetastaticcolorectalcancerinrealworldclinicalpractice